A new molecular imaging biomarker that is entering clinical trials could help monitor the proliferation of cancer cells and enable physicians to quickly determine the effectiveness of treatment.
The biomarker, fluorine 18 3-fluoro-3-deoxythymidine (FLT) could allow researchers and physicians to detect proliferation rates using hybrid imaging techniques such as PET-CT.
FLT helps demonstrate key steps in DNA replication, which precedes cell division. By imaging the biological processes within cancer cells, FLT could help physicians personalize cancer therapies through faster assessment of a specific therapy's effectiveness for an individual patient.
The U.S. Food ...